Combined Screening with PLGF (Delfia/LC)

Combined Screening with PLGF (Delfia/LC)

Test Overview

Combined Screening with PLGF (Placental Growth Factor) is an advanced first-trimester prenatal screening test used to assess the risk of chromosomal abnormalities and pregnancy-related complications. It combines maternal blood markers, ultrasound findings, and maternal age to provide a comprehensive risk assessment.

Why is this Test Done?

• Screens for chromosomal abnormalities such as:
  • Down Syndrome
  • Edwards Syndrome
  • Patau Syndrome
• Assesses the risk of developing Preeclampsia.
• Helps in early pregnancy management and monitoring.

Sample Required

• Maternal Serum (Blood Sample)

Method

• DELFIA/LC Technology

When is it Recommended?

• Between 11 and 13 weeks + 6 days of pregnancy.
• For all pregnant women, especially those with:
  • Advanced maternal age
  • Family history of genetic disorders
  • Previous pregnancy with chromosomal abnormalities

Benefits

✅ Early risk assessment for chromosomal conditions
✅ Non-invasive screening method
✅ Helps identify pregnancies at risk for preeclampsia
✅ Supports informed clinical decision-making

Preparation

• No fasting required.
• Ultrasound findings (Nuchal Translucency measurement) may be required for accurate risk calculation.

Interpretation

• Results indicate a risk estimate, not a definitive diagnosis.
• High-risk results may require confirmatory testing such as Chorionic Villus Sampling or Amniocentesis.

Early screening for a healthier pregnancy journey. 🩺👶

#Dermafact #gynofact #PrenatalScreening #PLGF #PregnancyCare #MaternalHealth #DownSyndromeScreening #PreeclampsiaScreening #AdvancedDiagnostics #BioCareLaboratories